193 related articles for article (PubMed ID: 38246924)
21. A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Park CS; Lewis AH; Chen TJ; Bridges CS; Shen Y; Suppipat K; Puppi M; Tomolonis JA; Pang PD; Mistretta TA; Ma L; Green MR; Rau R; Lacorazza HD
Blood; 2019 Nov; 134(22):1960-1972. PubMed ID: 31515251
[TBL] [Abstract][Full Text] [Related]
22. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
[TBL] [Abstract][Full Text] [Related]
23. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
[TBL] [Abstract][Full Text] [Related]
24. CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.
Wang Z; Chen CC; Chen W
Stem Cells; 2015 Dec; 33(12):3437-51. PubMed ID: 26466808
[TBL] [Abstract][Full Text] [Related]
25. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Morotti A; Panuzzo C; Fava C; Saglio G
Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
[TBL] [Abstract][Full Text] [Related]
26. Leukemia stem cells: the root of chronic myeloid leukemia.
Zhou H; Xu R
Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
[TBL] [Abstract][Full Text] [Related]
27. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
28. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells.
Buckle AM; Mottram R; Pierce A; Lucas GS; Russell N; Miyan JA; Whetton AD
Mol Med; 2000 Oct; 6(10):892-902. PubMed ID: 11126203
[TBL] [Abstract][Full Text] [Related]
29. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
[TBL] [Abstract][Full Text] [Related]
31. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
Lanza F; Bi S; Moretti S; Castoldi G; Goldman JM
Br J Haematol; 1995 May; 90(1):8-14. PubMed ID: 7786800
[TBL] [Abstract][Full Text] [Related]
32. Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis.
Toofan P; Wheadon H
Biochem Soc Trans; 2016 Oct; 44(5):1455-1463. PubMed ID: 27911727
[TBL] [Abstract][Full Text] [Related]
33. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
34. Chronic myeloid leukemia stem cells.
Houshmand M; Simonetti G; Circosta P; Gaidano V; Cignetti A; Martinelli G; Saglio G; Gale RP
Leukemia; 2019 Jul; 33(7):1543-1556. PubMed ID: 31127148
[TBL] [Abstract][Full Text] [Related]
35. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
[TBL] [Abstract][Full Text] [Related]
36. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
37. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
Carter BZ; Mak PY; Mu H; Wang X; Tao W; Mak DH; Dettman EJ; Cardone M; Zernovak O; Seki T; Andreeff M
Haematologica; 2020 May; 105(5):1274-1284. PubMed ID: 31371419
[TBL] [Abstract][Full Text] [Related]
39. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Cheloni G; Tanturli M; Tusa I; Ho DeSouza N; Shan Y; Gozzini A; Mazurier F; Rovida E; Li S; Dello Sbarba P
Blood; 2017 Aug; 130(5):655-665. PubMed ID: 28576876
[TBL] [Abstract][Full Text] [Related]
40. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]